Company Overview
GALECTIN THERAPEUTICS INC
GALTRevenue vs. Cost of Revenue
Revenue
Cost of Revenue
Total Operating Expenses vs. Operating Income
Total Operating Expenses
Operating Income
Net Income
Net Income
Revenue
—M
2025 FY
Net Income
-31M
2025 FY
Shares Outstanding
64M
2025 FY
EPS
-0.48USD
2025 FY
Company Information
SIC Code
2834
CIK Code
1133416
Exchange
Nasdaq
Location
US